Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03604289 · ClinicalTrials.gov registry record · Early Phase 1
Angiotensin 1-7 in Obesity Hypertension
A Early Phase 1 study, sponsored by Amy Arnold.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT03604289: Clinical Trial Early Phase 1 study, sponsored by Amy Arnold.
NCT03604289 is a Early Phase 1 study that was terminated before completion, run by Amy Arnold. The registered enrollment target is 8 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03604289, a Early Phase 1 study, was terminated before completion, sponsored by Amy Arnold.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if the investigational drug angiotensin-(1-7) improves cardiovascular health in patients with obesity and high blood pressure.
Primary Outcome
A blood pressure cuff will be inflated to a suprasystolic pressure for 5 minutes then deflated. Brachial artery diameter will be measured continuously before, during, and after cuff inflation using duplex ultrasound.
Interventions
- DRUG Saline
- DRUG Angiotensin-(1-7)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2023-06-03 |
| Phase | Early Phase 1 |
Why NCT03604289 stopped before completion
NCT03604289 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT03604289 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03604289 about?
NCT03604289 is a clinical study titled "Angiotensin 1-7 in Obesity Hypertension". The purpose of this study is to find out if the investigational drug angiotensin-(1-7) improves cardiovascular health in patients with obesity and high blood pressure.
What is the current status of trial NCT03604289?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2019-04-01. Estimated completion is 2023-06-03.
What interventions are being tested in trial NCT03604289?
The interventions under investigation include: Saline (DRUG), Angiotensin-(1-7) (DRUG).
Who is sponsoring clinical trial NCT03604289?
This trial is sponsored by Amy Arnold, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03604289's enrollment target sits among peer trials
8 1782nd of 2000 higher than 176 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI